SEP 20, 2019 06:43 PM PDT

Leukemia Drug Effective for Treating Childhood Brain Cancer

WRITTEN BY: Nouran Amin

Scientists at the University of California-San Diego have found that a chronic myeloid leukemia drug was found to treat medulloblastoma in mouse models more effectively than existing therapeutics. Findings of the study were published in PLOS One and demonstrates how the use of the single FDA-approved drug ‘nilotinib’ targets cancer cells that have been abnormally activated through a specific cell communication system known as the Hedgehog pathway.

Learn more about the Hedgehog Pathway:

"We discovered a previously unknown activity of nilotinib that may be leveraged to treat a large fraction of cases of medulloblastoma, a type of childhood brain cancer," said senior author Ruben Abagyan, PhD, professor in the Skaggs School of Pharmacy. "While more research is needed, this pharmaceutical could potentially be used for several cancer types with an overactive cell-signaling pathway."

Many types of cancer have an impaired hedgehog pathway such as basal cell carcinoma, myeloid leukemia, rhabdomyosarcoma, pancreatic adenocarcinoma, glioblastoma and one third of medulloblastoma cases. The Hedgehog pathway is a critical cellular system that regulates embryonic development and adult tissue regeneration. When impaired, the pathway allows the cancer cells to overproduce a cell-surface receptor known as smoothened—this results in plenty of malignant cancers.

In the study, Nilotinib was found to inhibit the activity of smoothened and several other protein kinases implicated in tumor growth. This was demonstrated in mice bearing human medulloblastoma tumors which after the Nilotinib-treatment tumor growth was decreased with no apparent drug resistance.

"Only a fraction of patients with this subtype of medulloblastoma respond well to current therapies that only target Smoothened," said Abagyan. "Knowing that dysregulation of the Hedgehog pathway is important to the maintenance of cancer stem cells, and that it plays a critical role in several cancers, we wanted to find a single drug that inhibits this pathway in addition to several other essential anti-cancer activities."

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
How Does Ecstasy Treat PTSD?
Conventionally, Post Traumatic Stress Disorder (PTSD) is treated via talk therapy, with the aim of getting patients to open up about their trauma and rewir...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Scientists Grow Mini Kidneys to Treat Kidney Disease
Current methods for testing potential treatments for kidney disease do not take genetic variation into account for how treatments may vary from patient to ...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Unprecedented Therapeutic Found Effective for Blood Cancer
According to the findings of a clinical trial, scientists at Mt. Sinai have found a new therapeutic effective for patients with a particular type of b...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
The Three Drugs that Reverse Biological Aging
In the last 100 years, life expectancy in the US has risen from 55 years until 79 (Roser: 2019). And with the continuous development of medicine and scie...
OCT 17, 2019
Immunology
OCT 17, 2019
A New Way To Fight Severe Peanut Allergies
Dr. Sandra Lin explains how SLIT is currently being used to treat allergies other than peanuts.    Over 1 million U.S. children have an allergy t...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Transplanted Brain Stem Cells Survive Without Anti-Rejection Drugs
Researchers at Johns Hopkins Medicine have successfully transplanted brain cells without the need of immune-suppressing drugs. Findings of the study were p...
Loading Comments...